Literature DB >> 33567048

Cost-Effective Trap qPCR Approach to Evaluate Telomerase Activity: an Important Tool for Aging, Cancer, and Chronic Disease Research.

Thalyta Nery Carvalho Pinto1, Juliana Ruiz Fernandes1, Liã Barbara Arruda2, Alberto José da Silva Duarte1, Gil Benard1,3.   

Abstract

OBJECTIVES: Telomeres are a terminal "DNA cap" that prevent chromosomal fusion and degradation. However, aging is inherent to life, and so is the loss of terminal sequences. Telomerase is a specialized reverse transcriptase encoded by self-splicing introns that counteract chromosome erosion. Telomerase activity is observed during early embryonic development, but after the blastocyst stage, the expression of telomerase reduces. The consequences of either insufficient or unrestrained telomerase activity underscore the importance of ongoing studies aimed at elucidating the regulation of telomerase activity in humans. In the present study, we aimed to standardize a simplified telomerase repeat-amplification protocol (TRAP) assay to detect telomerase activity in unstimulated and PHA-stimulated mononuclear cells. METHODS AND
RESULTS: Our optimized qPCR-based can efficiently evaluate telomerase activity. Quantification of protein and DNA between unstimulated and PHA-stimulated peripheral blood mononuclear cells revealed cellular activation and cell-cycle entry. The assay also showed that relative telomerase activity is significantly different between these two conditions, supporting the applicability of the assay. Furthermore, our findings corroborated that telomerase activity decreases with age.
CONCLUSIONS: Telomeres and telomerase are implicated in aging and development of chronic diseases and cancer; however, difficulty in accessing commercial kits to investigate these aspects is a critical constraint in health surveillance studies. Our optimized assay was successfully used to differentiate telomerase activity between unstimulated and stimulated cells, clearly showing the reactivation of telomerase upon cell activation. This assay is affordable, reproducible, and can be executed in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33567048      PMCID: PMC7847253          DOI: 10.6061/clinics/2021/e2432

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  55 in total

1.  Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age.

Authors:  N H Son; S Murray; J Yanovski; R J Hodes; N Weng
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

Review 2.  Switching and signaling at the telomere.

Authors:  E H Blackburn
Journal:  Cell       Date:  2001-09-21       Impact factor: 41.582

3.  Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide.

Authors:  T J Moriarty; S Dupuis; C Autexier
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

Review 4.  Detection of telomerase activity by the TRAP assay and its variants and alternatives.

Authors:  Jirí Fajkus
Journal:  Clin Chim Acta       Date:  2006-04-17       Impact factor: 3.786

5.  Up-regulation of telomerase activity in human lymphocytes.

Authors:  O Yamada; T Motoji; H Mizoguchi
Journal:  Biochim Biophys Acta       Date:  1996-12-12

6.  A PCR-free fluorescence strategy for detecting telomerase activity via double amplification strategy.

Authors:  Xiafei Zhang; Rui Cheng; Zhilu Shi; Yan Jin
Journal:  Biosens Bioelectron       Date:  2015-08-12       Impact factor: 10.618

7.  Telomere Length in Peripheral Blood Mononuclear Cells of Patients on Chronic Hemodialysis Is Related With Telomerase Activity and Treatment Duration.

Authors:  Ioannis Stefanidis; Georgios Voliotis; Vassilios Papanikolaou; Ioanna Chronopoulou; Theodoros Eleftheriadis; Axel Kowald; Elias Zintzaras; Aspasia Tsezou
Journal:  Artif Organs       Date:  2015-04-20       Impact factor: 3.094

8.  Telomerase activity: a biomarker of cell proliferation, not malignant transformation.

Authors:  C D Belair; T R Yeager; P M Lopez; C A Reznikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

9.  Telomere shortening in chronic obstructive pulmonary disease.

Authors:  Joyce M J Houben; Evi M Mercken; Hans B Ketelslegers; Aalt Bast; Emiel F Wouters; Geja J Hageman; Annemie M W J Schols
Journal:  Respir Med       Date:  2008-10-21       Impact factor: 3.415

10.  Inhibition of human telomerase activity by an engineered zinc finger protein that binds G-quadruplexes.

Authors:  Sachin D Patel; Mark Isalan; Gérald Gavory; Sylvain Ladame; Yen Choo; Shankar Balasubramanian
Journal:  Biochemistry       Date:  2004-10-26       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.